Clinical trials: Oxycodone
Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant…
- Trial name
- NCT01192295
- Testing
- Oxycodone HCl controlled-release tablets
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 155 people
- Sponsor
- Purdue Pharma LP
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
- Trial name
- NCT00092313
- Testing
- MK0966, rofecoxib, Comparator: oxycodone and acetaminophen
- Volunteers
- 271 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
- Trial name
- NCT00092326
- Testing
- MK0966, rofecoxib
- Volunteers
- 269 people
- Sponsor
- Merck Sharp & Dohme LLC
Pain
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
The objective of this study is to characterize the pharmacokinetics and to evaluate the safety of single and multiple doses of Oxycodone Oral Solution in pediatric and adolescent subjects for postoperative pain.
- Trial name
- NCT01959204
- Testing
- Oxycodone
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- VistaPharm, Inc.
Moderate-severe Pain
Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
- Trial name
- NCT02680847
- Testing
- ALO-02
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pfizer
Pain
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged 6 to 17 years, inclusive, with moderate to severe…
- Trial name
- NCT01369615
- Testing
- Oxycodone hydrochloride controlled-release tablets
- Where
- 14 sites in United States, Israel
- Volunteers
- 23 people
- Sponsor
- Purdue Pharma LP
Pain
Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction
A clinical, multicenter, randomized, parallel-group, double-blind, double-dummy, comparative study of non-inferiority. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is…
- Trial name
- OXIFEN (NCT05081102)
- Testing
- FDC of oxycodone 5 mg/ibuprofen 400 mg, Tylex
- Where
- Brazil
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Acute Pain
Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain
Phase 4, multicenter, open-label, multiple-dose study of the pharmacokinetics (PK) and safety of XARTEMIS XR in postsurgical adolescent subjects aged 12 to 17 years with moderate to severe acute pain.
- Trial name
- NCT02508935
- Testing
- XARTEMIS XR
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mallinckrodt
Opioid Analgesia
Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients
The purpose of this study is to characterize the pharmacokinetics (PK) of single-dose ORF tablets in pediatric patients aged 6 to 16 years, inclusive.
- Trial name
- NCT01160614
- Testing
- Oxycodone hydrochloride controlled-release (ORF) tablets
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Purdue Pharma LP